SCHEMBL30821970

SCHEMBL30821970

COC(=O)c1cc(F)cc(C(=O)Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.50
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
LMNA P02545 3/20 0.50
CA12 O43570 2/20 0.48
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA7 P43166 2/20 0.48
CA9 Q16790 2/20 0.48
CA14 Q9ULX7 2/20 0.48
MAPT P10636 4/20 0.47
POLB P06746 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
XDH P47989 2/20 0.47
GAA P10253 1/20 0.47
NFKB1 P19838 1/20 0.47
GFER P55789 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
FUT7 Q11130 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1401499 0.90 CA1 (0.58) KDM4EMEN1KMT2ALMNACA12
SCHEMBL4531505 0.90 CA1 (0.58) KDM4EMEN1KMT2ALMNACA12
SCHEMBL521670 0.86 CA1 (0.58) KDM4EMEN1KMT2ALMNACA12
SCHEMBL2293145 0.83 CES2 (0.55) MEN1KMT2ACA12CA1CA2
SCHEMBL16952776 0.82 KDM4E (0.51) KDM4EMEN1KMT2ALMNACA12
SCHEMBL1544732 0.82 HCAR1 (0.53) KDM4EMEN1KMT2ALMNACA12
SCHEMBL30822018 0.82 HCAR1 (0.53) KDM4EMEN1KMT2ALMNACA12
SCHEMBL8978079 0.82 CA12 (0.73) KDM4EMEN1KMT2ALMNACA12
SCHEMBL30642568 0.81 MEN1 (0.50) KDM4EMEN1KMT2ALMNACA12
SCHEMBL5227070 0.81 CA1 (0.48) KDM4EMEN1KMT2ALMNACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326777-A1 COMPOUNDS, COMPOSITIONS AND METHODS THEREOF HEPAITECH BEIJING BIOPHARMA TECH CO LTD (CN) 2025-10-23 US disclosed
EP-4605374-A1 COMPOUNDS, COMPOSITIONS AND METHODS THEREOF Hepaitech (Beijing) Biopharma Technology Co., Ltd. (CN) 2025-08-27 EP disclosed
CN-120129676-A Compounds, compositions, and methods thereof 海湃泰克(北京)生物医药科技有限公司 2025-06-10 CN disclosed
WO-2024083210-A1 COMPOUNDS, COMPOSITIONS AND METHODS THEREOF HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) 2024-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326777-A1 COMPOUNDS, COMPOSITIONS AND METHODS THEREOF MRGPRX4, MRGPRX1, MRGPRX2 KDM4E 2213/4885MEN1 1133/4885KMT2A 2511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.